$804.08
0.11% today
NYSE, Jan 29, 10:10 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$804.99
+31.15 4.03% 1M
-2.80 0.35% 6M
+32.99 4.27% YTD
+159.99 24.80% 1Y
+559.89 228.43% 3Y
+665.73 478.05% 5Y
+734.02 1,034.27% 10Y
NYSE, Closing price Tue, Jan 28 2025
-3.18 0.39%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $764.19b
Enterprise Value $791.87b
P/E (TTM) P/E ratio 88.06
EV/FCF (TTM) EV/FCF 565.70
EV/Sales (TTM) EV/Sales 19.38
P/S ratio (TTM) P/S ratio 18.70
P/B ratio (TTM) P/B ratio 53.72
Dividend yield 0.65%
Last dividend (FY24) $5.20
Revenue growth (TTM) Revenue growth 27.41%
Revenue (TTM) Revenue $40.86b
EBIT (operating result TTM) EBIT $14.44b
Free Cash Flow (TTM) Free Cash Flow $1.40b
Cash position $3.52b
EPS (TTM) EPS $9.14
P/E forward 66.32
P/S forward 16.87
EV/Sales forward 17.48
Short interest 0.90%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Eli Lilly and Company forecast:

24x Buy
75%
7x Hold
22%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Eli Lilly and Company forecast:

Buy
75%
Hold
22%
Sell
3%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
40,863 40,863
27% 27%
100%
- Direct Costs 7,803 7,803
14% 14%
19%
33,061 33,061
31% 31%
81%
- Selling and Administrative Expenses 6,424 6,424
15% 15%
16%
- Research and Development Expense 10,531 10,531
20% 20%
26%
16,106 16,106
48% 48%
39%
- Depreciation and Amortization 1,670 1,670
10% 10%
4%
EBIT (Operating Income) EBIT 14,436 14,436
54% 54%
35%
Net Profit 8,370 8,370
68% 68%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Neutral
Seeking Alpha
about 3 hours ago
I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation multiples are justified by robust growth prospects in FY2025 and FY2026 (likely beyond that as well). Risks include competition from Novo Nordisk and potential pricing pressures, which could impact margins a...
Neutral
Business Wire
about 7 hours ago
INDIANAPOLIS--(BUSINESS WIRE)--Generation Z, Millennial donors are issue driven and technology focused, report shows.
Neutral
MarketBeat
one day ago
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S NYSE: NVO were likely the hottest medical sector story in 2024. With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. NYSE: LLY was another key pharma player in this new type of treatment for diabetes and obesity.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 43,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today